162 related articles for article (PubMed ID: 10160102)
1. Cost considerations in the drug treatment of hypertension. Is older better?
Kaplan NM
Pharmacoeconomics; 1996 Apr; 9(4):283-5. PubMed ID: 10160102
[No Abstract] [Full Text] [Related]
2. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension].
Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L
Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623
[No Abstract] [Full Text] [Related]
3. Hypertension treatment and control in Sub-saharan Africa. Figure of $1800 per life saved seems optimistic.
Burdon J
BMJ; 1998 Jul; 317(7150):76; author reply 77. PubMed ID: 9651283
[No Abstract] [Full Text] [Related]
4. [Medical economics of hypertension therapy].
Yamazaki T
Nihon Rinsho; 2008 Aug; 66(8):1601-4. PubMed ID: 18700564
[No Abstract] [Full Text] [Related]
5. NIH promotes use of lower cost drugs for hypertension.
Spurgeon D
BMJ; 2004 Mar; 328(7439):539. PubMed ID: 15001483
[No Abstract] [Full Text] [Related]
6. [Pharmacotherapy of hypertension. How much can safely be saved?].
Anlauf M
MMW Fortschr Med; 2004 Apr; 146(15):57-8. PubMed ID: 15373022
[No Abstract] [Full Text] [Related]
7. [Pharmacoeconomic analysis of antihypertensive therapy: advantages of fixed combinations].
Leonova MV; Erofeeva SB; Bykov AV; Belousov IuB
Kardiologiia; 2008; 48(1):43-50. PubMed ID: 18260995
[No Abstract] [Full Text] [Related]
8. Health economic issues and the future treatment and management of hypertension.
Giles TD
AAPPO J; 1994; 4(4):27-8, 30, 33-5. PubMed ID: 10150589
[No Abstract] [Full Text] [Related]
9. Should we spend less or control a greater percentage of hypertensive patients?
Mion D; Ortega KC
Sao Paulo Med J; 2002 Jul; 120(4):99. PubMed ID: 12436154
[No Abstract] [Full Text] [Related]
10. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
Wilson TW; Chockalingam A; Quest DW
J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
[TBL] [Abstract][Full Text] [Related]
11. Differences in medical expenditure according to drug prices.
Ueshima H
Hypertens Res; 2006 May; 29(5):301-2. PubMed ID: 16832148
[No Abstract] [Full Text] [Related]
12. [Real and assumed potential savings in antihypertensive treatment. Right out of the magician's hat].
Anlauf M; Hense HW
Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1557-9. PubMed ID: 12854069
[No Abstract] [Full Text] [Related]
13. Access to Antihypertensive Drugs in China.
Bai G; Bennet C; Wang J; Anderson GF
Circulation; 2018 Oct; 138(17):1777-1779. PubMed ID: 30354658
[No Abstract] [Full Text] [Related]
14. [Comment on IOWiG report plan. A medical decision may not be replaced].
Vorstand der Deutschen Hochdruckliga E.V
MMW Fortschr Med; 2006 May; 148(19):42. PubMed ID: 16736705
[No Abstract] [Full Text] [Related]
15. The financial cost of optimising blood pressure control.
Shiner T; Simons L; Parkinson H; Khanbhai A; Karthikeyan VJ; Nandhara G; Beevers DG
J Hum Hypertens; 2005 Jan; 19(1):83-4. PubMed ID: 15372065
[TBL] [Abstract][Full Text] [Related]
16. [Economy, costs and drug choices in cardiology. A reflection on the 2012 position paper of the Italian Society of Hypertension].
Camerini F; Palcic S
G Ital Cardiol (Rome); 2013 Jun; 14(6):412-5. PubMed ID: 23748537
[No Abstract] [Full Text] [Related]
17. Cost of hypertension treatment.
Odell TW; Gregory MC
J Gen Intern Med; 1995 Dec; 10(12):686-8. PubMed ID: 8770721
[TBL] [Abstract][Full Text] [Related]
18. [The pharmaco-economics of the treatment of arterial hypertension: data and controversies].
Rorive G; Delporte JP
Bull Mem Acad R Med Belg; 1998; 153(7-9):317-21; discussion 322-4. PubMed ID: 10100395
[TBL] [Abstract][Full Text] [Related]
19. A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension.
Doyle J; Omvik P; Arikian S; Casciano J; Casciano R; Gonzalez MA; Arocho R
Manag Care Interface; 2001 Mar; 14(3):82-7. PubMed ID: 11301961
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensive treatment - navigating between cost, compliance and complications.
Conen D
Swiss Med Wkly; 2013; 143():w13857. PubMed ID: 24163056
[No Abstract] [Full Text] [Related]
[Next] [New Search]
